Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001193125-22-199872
Filing Date
2022-07-22
Accepted
2022-07-22 13:34:00
Documents
2
Group Members
NESTLE S.A.NESTLE US HOLDCO, INC.NIMCO US, INC.SOCIETE DES PRODUITS NESTLE S.A.

Document Format Files

Seq Description Document Type Size
1 SC 13D/A d749333dsc13da.htm SC 13D/A 98445
2 EX-99.3 d749333dex993.htm EX-99.3 26167
  Complete submission text file 0001193125-22-199872.txt   126370
Mailing Address 200 SIDNEY STREET CAMBRIDGE MA 02139
Business Address 200 SIDNEY STREET CAMBRIDGE MA 02139 617 945 9626
Seres Therapeutics, Inc. (Subject) CIK: 0001609809 (see all company filings)

EIN.: 274326290 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-88909 | Film No.: 221099522
SIC: 2834 Pharmaceutical Preparations

Mailing Address C/O NESTLE USA, INC. 800 NORTH BRAND BLVD. GLENDALE CA 91203
Business Address C/O NESTLE USA, INC. 800 NORTH BRAND BLVD. GLENDALE CA 91203 (818) 548-7050
Nestle Health Science US Holdings, Inc. (Filed by) CIK: 0001644164 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A